In vitro and in vivo activities of OP0595, a new diazabicyclooctane, against CTX-M-15-positive Escherichia coli and KPC-positive Klebsiella pneumoniae

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 5, 2016, Pages 3001-3006

  Morinaka, Akihiro ^a   Tsutsumi, Yuko ^a   Yamada, Keiko ^a   Takayama, Yoshihiro ^a   Sakakibara, Shiro ^a   Takata, Toshihiko ^a   Abe, Takao ^a   Furuuchi, Takeshi ^a   Inamura, Seiichi ^a   Sakamaki, Yoshiaki ^a   Tsujii, Nakako ^a   Ida, Takashi ^a  

^a MEIJI SEIKA KAISHA LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AZABICYCLO DERIVATIVE; BETA LACTAMASE; CEFEPIME; CEPHALOSPORIN DERIVATIVE; LACTAM; MEROPENEM; NACUBACTAM; PIPERACILLIN; THIENAMYCIN DERIVATIVE;

DRUG EFFECTS; ESCHERICHIA COLI; KLEBSIELLA PNEUMONIAE; METABOLISM; MICROBIAL SENSITIVITY TEST;

AZABICYCLO COMPOUNDS; BETA-LACTAMASES; CEPHALOSPORINS; ESCHERICHIA COLI; KLEBSIELLA PNEUMONIAE; LACTAMS; MICROBIAL SENSITIVITY TESTS; PIPERACILLIN; THIENAMYCINS;

EID: 84964882133     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02704-15     Document Type: Article

References (24)

1. Bush K. 2013. Proliferation and significance of clinically relevant β-lactamases. Ann N Y Acad Sci 1277:84-90. http://dx.doi.org/10.1111/nyas.12023.
2. Bush K, Jacoby GA. 2010. Updated functional classification of β-lactamases. Antimicrob Agents Chemother 54:969-976. http://dx.doi.org/10.1128/AAC.01009-09.
3. Gupta N, Limbago BM, Patel JB, Kallen AJ. 2011. Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention. Clin Infect Dis 53:60-67. http://dx.doi.org/10.1093/cid/cir202.
4. Munoz-Price LS, Poirel L, Bonomo RA, Schwaber MJ, Daikos GL, Cormican M, Cornaglia G, Garau J, Gniadkowski M, Hayden MK, Kumarasamy K, Livermore DM, Maya JJ, Nordmann P, Patel JB, Paterson DL, Pitout J, Villegas MV, Wang H, Woodford N, Quinn JP. 2013. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis 13:785-796. http://dx.doi.org/10.1016/S1473-3099(13)70190-7.
5. Tumbarello M, Viale P, Viscoli C, Trecarichi EM, Tumietto F, Marchese A, Spanu T, Ambretti S, Ginocchio F, Cristini F, Losito AR, Tedeschi S, Cauda R, Bassetti M. 2012. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase producing K. pneumoniae: importance of combination therapy. Clin Infect Dis 55:943-950. http://dx.doi.org/10.1093/cid/cis588.
6. Watkins RR, Papp-Wallace KM, Drawz SM, Bonomo RA. 2013. Novelβ-lactamase inhibitors: a therapeutic hope against the scourge of multidrug resistance. Front Microbiol 4:392. http://dx.doi.org/10.3389/fmicb.2013.00392.
7. Morinaka A, Tsutsumi Y, Yamada M, Suzuki K, Watanabe T, Abe T, Furuuchi T, Inamura S, Sakamaki Y, Mitsuhashi N, Ida T, Livermore DM. 2015. OP0595, a new diazabicyclooctane: mode of action as a serineβ-lactamase inhibitor, antibiotic and β-lactam 'enhancer'. J Antimicrob Chemother 70:2779-2786. http://dx.doi.org/10.1093/jac/dkv166.
8. Zhanel GG, Lawson CD, Adam H, Schweizer F, Zelenitsky S, Lagacé-Wiens PR, Denisuik A, Rubinstein E, Gin AS, Hoban DJ, Lynch JP, III, Karlowsky JA. 2013. Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination. Drugs 73:159-177. http://dx.doi.org/10.1007/s40265-013-0013-7.
9. Livermore DM, Mushtaq S, Warner M, Zhang J, Maharjan S, Doumith M, Woodford N. 2011. Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-producing Enterobacteriaceae. Antimicrob Agents Chemother 55:390-394. http://dx.doi.org/10.1128/AAC.00756-10.
10. Hirsch EB, Ledesma KR, Chang KT, Schwartz MS, Motyl MR, Tam VH. 2012. In vitro activity of MK-7655, a novel β-lactamase inhibitor, in combination with imipenem against carbapenem-resistant Gram-negative bacteria. Antimicrob Agents Chemother 56:3753-3757. http://dx.doi.org/10.1128/AAC.05927-11.
11. Livermore DM, Warner M, Mushtaq S. 2013. Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa. J Antimicrob Chemother 68:2286-2290. http://dx.doi.org/10.1093/jac/dkt178.
12. Yagi T, Kurokawa H, Shibata N, Shibayama K, Arakawa Y. 2000. A preliminary survey of extended-spectrum beta-lactamases (ESBLs) in clinical isolates of Klebsiella pneumoniae and Escherichia coli in Japan. FEMS Microbiol Lett 184:53-56. http://dx.doi.org/10.1111/j.1574-6968.2000.tb08989.x.
13. Clinical and Laboratory Standards Institute. 2015. Performance standards for antimicrobial susceptibility testing: twenty-third informational supplement M100-S25. Clinical and Laboratory Standards Institute, Wayne, PA.
14. Clinical and Laboratory Standards Institute. 2015. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically-ninth edition: approved standard M7-A10. Clinical and Laboratory Standards Institute, Wayne, PA.
15. Clinical and Laboratory Standards Institute. 1999. Methods for determining bactericidal activity of antimicrobial agents; approved guideline M26-A. Clinical and Laboratory Standards Institute, Wayne, PA.
16. Craig WA, Andes DR. 2013. In vivo activities of ceftolozane, a new cephalosporin, with and without tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, including strains with extended-spectrum β-lactamases, in the thighs of neutropenic mice. Antimicrob Agents Chemother 57:1577-1582. http://dx.doi.org/10.1128/AAC.01590-12.
17. Melchers MJ, van Mil AC, Mouton JW. 2015. In vitro activity of ceftolozane alone and in combination with tazobactam against extendedspectrum-β-lactamase-harboring Enterobacteriaceae. Antimicrob Agents Chemother 59:4521-4525. http://dx.doi.org/10.1128/AAC.04498-14.
18. Livermore DM, Mushtaq S, Warner M, Woodford N. 25 August 2015. Activity of OP0595/β-lactam combinations against Gram-negative bacteria with extended-spectrum, AmpC and carbapenem-hydrolysing β-lactamases. J Antimicrob Chemother http://dx.doi.org/10.1093/jac/dkv239.
19. Doumith M, Mushtaq S, Livermore DM, Woodford N. 2015. Molecular mechanisms raising MICs of the new diazabicyclooctane, OP0595, for Escherichia coli, abstr C-120. Abstr 55th Intersci Conf Antimicrob Agents Chemother-28th Intersci Congr Chemother Meet. American Society for Microbiology and International Society of Chemotherapy, San Diego, CA.
20. Thulin E, Sundqvist M, Andersson DI. 2015. Amdinocillin (Mecillinam) resistance mutations in clinical isolates and laboratory-selected mutants of Escherichia coli. Antimicrob Agents Chemother 59:1718-1727. http://dx.doi.org/10.1128/AAC.04819-14.
21. Livermore DM, Warner M, Mushtaq S, Woodford N. 2014. Activity of OP0595-β-lactam combinations vs. OP0595-resistant Enterobacteriaceae mutants, abstr F-943. Abstr 54th Intersci Conf Antimicrob Agents Chemother. American Society for Microbiology, Washington, DC.
22. Singh R, Kim A, Tanudra MA, Harris JJ, McLaughlin RE, Patey S, O'Donnell JP, Bradford PA, Eakin AE. 2015. Pharmacokinetics/pharmacodynamics of a β-lactam and β-lactamase inhibitor combination: a novel approach for aztreonam/avibactam. J Antimicrob Chemother 70:2618-2626. http://dx.doi.org/10.1093/jac/dkv132.
23. Louie A, Castanheira M, Liu W, Grasso C, Jones RN, Williams G, Critchley I, Thye D, Brown D, Vanscoy B, Kulawy R, Drusano GL. 2012. Pharmacodynamics of β-lactamase inhibition by NXL104 in combination with ceftaroline: examining organisms with multiple types ofβ-lactamases. Antimicrob Agents Chemother 56:258-270. http://dx.doi.org/10.1128/AAC.05005-11.
24. VanScoy B, Mendes RE, Nicasio AM, Castanheira M, Bulik CC, Okusanya OO, Bhavnani SM, Forrest A, Jones RN, Friedrich LV, Steenbergen JN, Ambrose PG. 2013. Pharmacokinetics-pharmacodynamics of tazobactam in combination with ceftolozane in an in vitro infection model. Antimicrob Agents Chemother 57:2809-2814. http://dx.doi.org/10.1128/AAC.02513-12.